SCHEMBL3335983

SCHEMBL3335983

CC(=O)c1c[c]cc(Cc2c[c]cc(C(C)=O)c2)c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.48
LMNA P02545 3/20 0.42
MAPT P10636 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CA5A P35218 1/20 0.37
CYP19A1 P11511 1/20 0.33
PKM P14618 1/20 0.32
POLB P06746 1/20 0.32
PRKCI P41743 1/20 0.32
HSD17B10 Q99714 1/20 0.32
CA2 P00918 1/20 0.32
S100A4 P26447 1/20 0.32
IL4I1 Q96RQ9 1/20 0.31
MAOB P27338 1/20 0.31
GSK3B P49841 1/20 0.31
L3MBTL1 Q9Y468 2/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2887729 0.82 CA5A (0.46) KMT2ALMNAMAPTCA5APKM
SCHEMBL8580812 0.75 KMT2A (0.58) KMT2ALMNAMAPTNPSR1CA5A
SCHEMBL3950723 0.74 CA5A (0.56) KMT2ALMNAMAPTCA5APKM
SCHEMBL17256645 0.72 CES2 (0.39) LMNAMAPTNPSR1CA5AMAOB
SCHEMBL27617295 0.72 CA5A (0.38) KMT2ALMNAMAPTCA5APOLB
SCHEMBL3995446 0.72 IL4I1 (0.45) KMT2ALMNACYP19A1CA2IL4I1
SCHEMBL8319196 0.69 LMNA (0.42) KMT2ALMNAMAPTCA2L3MBTL1
SCHEMBL16955469 0.69 ALDH1A1 (0.50) KMT2APKMNPC1RAB9A
SCHEMBL2879040 0.69 MAPT (0.38) KMT2AMAPTCA5APKMHSD17B10
SCHEMBL3335985 0.68 LMNA (0.59) KMT2ALMNAIL4I1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144872-A1 New Methylenebisphenyl Compounds Useful in the Treatment of Inflammation BIOLIPOX AB 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144872-A1 New Methylenebisphenyl Compounds Useful in the Treatment of Inflammation LTC4S, LTB4R2, LTB4R KMT2A 4008/4885LMNA 1200/4885MAPT 4518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.